Cost-effectiveness of losartan versus atenolol in treating hypertension - An analysis of the LIFE study from a Swiss perspective

Cardiovascular Drugs and Therapy

Volumn 18, Issue 5, 2004, Pages 391-397

  Szucs, Thomas D ^a   Burnier, Michel ^b   Erne, Paul ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

Atenolol; Cost effectiveness; Hypertension; LIFE; Medical economics; Stroke losartan

Indexed keywords

ATENOLOL; LOSARTAN;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; STROKE; SURVIVAL;

AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; HYPERTENSION; LIFE EXPECTANCY; LOSARTAN; MALE; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDIES; SWITZERLAND;

EID: 17644388834     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-5064-x     Document Type: Article

References (28)

1. Zerebrovaskuläre Arbeitsgruppe der Schweiz und Schweizerische Herzstiftung. Epidemiologie des Hirnschlages. Schweizerische Ärztezeitung 2000;81:835-840.
2. Collins R, McMahon S. Blood pressure, antihypertensive drug treatment and risks of stroke and of coronary heart disease. Br Mod Bull 1994;50:272-298.
3. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-795.
4. Goa KL, Wagstaff AJ. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-845.
5. Dahlöf B, Lindholm LH. Losartan for cardiovascular disease in patients with and without diabetics in the LIFE study (author reply). Lancet 2002;359:2203-2204.
6. Sandoz MS, Ess SM, Furrer J, Szucs TD. Medical economic benefits of losartan in patients with type 2 diabetes and nephropathy: The Renaal Study Economic Evaluation in the Swiss Healthcare Setting. Poster presented at European Congress on the Study of Diabetes, Budapest, 2002.
7. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;23;359:995-1003.
8. Dahlof B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: Rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-713.
9. Swiss Drug Compendium 2003; Documed, Basel, 2003.
10. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651-659.
11. Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost Effectiveness in Health and Medicine. Recommendations on reporting cost-effectiveness analyses. JAMA 1996;276:1339-1341.
12. Office of Social Insurance. Handbook for the Economic Assessment of Health- care Technologies. Bern, 2002.
13. Beck JR, Kassirer JP, Pauker SG, et al. A convenient approximation of life expectancy - the DEALE. I. Validation of the method. Am J Med 1982;73,883-888.
14. Beck JR, Kassirer JP, Pauker SG, et al. A convenient approximation of life expectancy - The DEALE. II. Use in medical decision-making. Am J Med 1982;73:889-897.
15. Statistisches Jahrbuch der Schweiz, Verlag NZZ, Zürich, 2000.
16. Naegeli B, Bertel O, Urban P, et al. Der akute Myokardinfarkt in der Schweiz: Resultate aus dem PIMICS-Herzinfarkt Register. Schweiz med Wschr 1998;128:729-736.
17. Devereux RB, Dahlof B, Kjeldsen SE, et al. Cardiovascular mortality in patients without pre-existing vascular disease in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Abstracts from American Heart Association Scientific Sessions 2002, November 17-20, 2002; Chicago, Illinois. Circulation 2002;106(suppl II):II-475. Abstract 2352.
18. Schmitt-Koopmann I, Schwenkglenks M, Spinas G, Szucs TD. Direct medical costs of type 2 diabetes and its complications in Switzerland. European J Publ Health 2004;14(1):3-9.
19. Ess SM, Szucs TD. High dose lisinopril in heart failure: Economic considerations. Cardiovascular Drugs and Therapy 2002;16:365-371.
20. Szucs T, Berger K, Schulte-Hillen, Kleber FX. Die Wirtschaftlichkeit von Captopril nach Myokardinfarkt. Med Klinik 1996;91:112-118.
21. Goldmann L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adreneric antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-157.
22. Szucs TD, Bertel O, Darioli R, Gutzwiller F, Mordasini R. Ökonomische Evaluation von Pravastatin in der Behandlung der koronaren Sekundärprävention. Eine Analyse auf der Basis der LIPID Studie (Economical and pharmacological valuation of pravastatin in secondary coronary prevention). Schw Rundschau Med Praxis 2000;57:1667-1673.
23. Taylor WC, Pass TM, Shephard DS, Komaroff AL. Cost-effectiveness of cholesterol reduction for the primary prevention of coronary heart disease in men. Preventing disease: Beyond the rhetoric. New York: Springer, 1990.
24. Cathomas G, Erne P, Schwenkglenks M, Szucs T. The economic efficiency of Amlodipine on the treatment of coronary Atherosclerosis - an analysis based on the PREVENT study. Cardiovasc Drugs Ther 2002;16:61-66.
25. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977;296:732-739.
26. Szucs TD, Müller D, Darioli R. Schweizer Analyse der ASCOT-Studie: Wie kosten-effektiv sind Statinen in der coronaren Prävention? Cardiovasc 2003;5:29-32.
27. Haldemann R, Lüscher TF, Szucs TD. Die Wirtschaftlichkeit von Clopidogrel in der kardiovaskulären Sekundärprävention: eine Kosten-Effektivitäts-Analyse auf der Grundlage der CAPRIE-Studie. [Cost Effectiveness of Clopidogrel in the Secondary Prevention of Major Cardiovascular Events] Praxis 2001;90:539-545.
28. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl JMed 1995;332:1418-1431.